1 / 11

Advisory Committee for Pharmaceutical Science

Advisory Committee for Pharmaceutical Science. Sterilization Options Kristen D. Evans Investigative Engineer, USFDA October 22, 2002. 10/22/02 OPS Advisory Committee - Aseptic Processing.

jacob
Download Presentation

Advisory Committee for Pharmaceutical Science

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Advisory Committee for Pharmaceutical Science Sterilization Options Kristen D. Evans Investigative Engineer, USFDA October 22, 2002 10/22/02 OPS Advisory Committee - Aseptic Processing

  2. Sterile Drug Products Produced by Aseptic ProcessingDraft Concept Paper, Section III. Scope (lines 52-58) “It is a well-accepted principle that sterile drugs should be manufactured by aseptic processing only when terminal sterilization is not feasible.” “[Otherwise,] adjunct processing steps (e.g., heat exposure conditions which provide some FO ) to increase the level of sterility confidence should be considered.”

  3. Terms • PNSU - Probability of a Non-Sterile Unit • The probability of a unit (product container) being non-sterile after the application of a lethal agent. • PNSU of 1 in 106 -- the probability that a unit is non-sterile is one in a million • FO - Sterilization Process Equivalent Time • The equivalent number of minutes at 121.1°C delivered to a unit by a sterilization process. • FO = 8 minutes -- the cycle delivered a microbial lethality equivalent to 8 minutes at 121.1°C

  4. PDA Technical Report #36: Current Practices in the Validation of Aseptic Processing - 2001 At your site, is aseptic processing used for products that could be terminally sterilized? For this response, “could be terminally sterilized” means capable of withstanding a steam sterilization cycle with FO>8 minutes.

  5. 85% No 67.4% Yes 32.6% 30% (mean) 2% If Yes, then percentage of products affected n = 43 At your site, is aseptic processing used for products that could be terminally sterilized? Source: PDA Technical Report #36: Current Practices in the Validation of Aseptic Processing - 2001

  6. Probability of a Non-Sterile Unit (PNSU) Terminal Sterilization • Designed and qualified for a PNSU > 1 in 106 • Generally only one critical system to control Aseptic Processing • Impossible to scientifically determine a PNSU • Many critical systems involved • “Contamination Rate” assessed with media fills

  7. Probability of a Non-Sterile UnitAseptic (Estimated*) vs. Terminal Percentage of Firms (n=40) 102 103 104 105 106 107 Probability of a Non-Sterile Unit (1 in …) * Aseptic processing PNSU estimates from PDA TR#36, 2001

  8. RecallsLack of Sterility Assurance Number of Recalls Fiscal Year • Lack of Sterility Assurance is the #1 reason for drug recalls in last 5 years • Nearly all drugs recalled due to Lack of Sterility Assurance in last 20 years were produced via aseptic processing

  9. Global SceneEuropean Agency for the Evaluation of Medicinal Products (EMEA) From: Decision Trees for the Selection of Sterilization Methods (10/1999) • Terminal Sterilization Fo > 15 minutes • “Adjunct” Processing • Fo > 8 minutes, and • PNSU > 1 in 106 Aseptic Processing

  10. Global SceneEuropean Agency for the Evaluation of Medicinal Products (EMEA) “Where a choice is made not to utilise a method of terminal sterilization, … proper scientific explanation and justification should be provided in the dossier.” “Heat lability of a packaging material should not in itself be considered as adequate justification for not utilising terminal sterilisation, for otherwise heat stable products.” From: EMEA Note for Guidance on Development Pharmaceutics (July, 1998)

  11. Questions for Advisory Committee Should terminal sterilization be used when feasible? Should adjunct processing be considered in order to increase confidence in aseptically processed products?

More Related